Retraction to "Thyroid Cancer Cell Resistance to Gefitinib Depends on the Constitutive Oncogenic Activation of the ERK Pathway"
- PMID: 36848947
- DOI: 10.1210/clinem/dgad056
Retraction to "Thyroid Cancer Cell Resistance to Gefitinib Depends on the Constitutive Oncogenic Activation of the ERK Pathway"
Retraction of
-
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.J Clin Endocrinol Metab. 2013 Jun;98(6):2502-12. doi: 10.1210/jc.2012-3623. Epub 2013 Apr 4. J Clin Endocrinol Metab. 2013. Retraction in: J Clin Endocrinol Metab. 2023 Apr 13;108(5):e207. doi: 10.1210/clinem/dgad056. PMID: 23559083 Retracted.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous